With patent con­cerns loom­ing, Roche gets a new pri­or­i­ty re­view on block­buster IPF drug

Sev­en years af­ter the FDA first ap­proved Es­bri­et, the block­buster Roche IPF drug is get­ting an ex­pe­dit­ed re­view for a sec­ond in­di­ca­tion.

On Thurs­day, the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER